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Abstract	26	
Methylxanthines	 are	 the	most	 widely	 consumed	 drugs	 in	 the	 world	 and	 evidence	 of	 their	 health	27	
benefits	has	been	growing	in	recent	years.	Primary	Amine	Oxidase	(PrAO)	has	been	recognised	as	a	28	
therapeutic	 target	 for	 amelioration	 of	 inflammatory,	 vascular	 and	 neurodegenerative	 diseases.	29	
Previous	work	 in	our	 laboratories	 showed	 that	 caffeine	 inhibited	Bovine	PrAO	with	a	Ki	of	1.0mM	30	
using	benzylamine	as	substrate.		31	
This	 study	 aimed	 to	 extend	 our	 previous	 work	 and	 explore	 the	 possibility	 that	 related	32	
methylxanthines	 might	 influence	 PrAO	 activity.	 While	 paraxanthine,	 theophylline	 and	 7-33	
methylxanthine	had	little	effect	on	PrAO,	theobromine	was	a	noncompetitive	 inhibitor	with	a	Ki	of	34	
276±44µM.	The	specific	structural	elements	of	methylxanthines	that	are	required	for	inhibition	allow	35	
us	to	suggest	that	their	binding	site	on	PrAO	may	be	a	target	for	therapeutics.	The	health	benefits	36	
associated	with	dietary	methylxanthine	consumption	could	involve	PrAO	inhibition.		37	
	38	
Practical	Applications	39	
Inhibition	of	PrAO	by	methylxanthines	may	be	significant	in	conferring	health	benefits.	The	design	of	40	
PrAO	 inhibitors	 based	 on	 the	 structural	 motifs	 identified	 in	 this	 study	 (N-methylation	 at	 specific	41	
locations)	is	indicated.	Existing	therapeutics	based	on	a	core	xanthine	structure	can	be	evaluated	for	42	
their	effects	on	PrAO.	Moreover,	PrAO	inhibition	must	be	considered	as	a	potential	mediator	of	the	43	
beneficial	health	effects	of	some	methylxanthines.	If	inhibition	in	human	tissues	is	comparable	to,	or	44	
greater	 than,	 that	 found	 in	 these	 studies	 it	 points	 to	 an	 important	 role	 for	 these	 compounds	 in	45	
human	health.		46	
47	
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Introduction	48	
Caffeine,	a	methylxanthine,	is	among	the	most	world’s	most	widely	consumed	drugs.	In	recent	years,	49	
evidence	of	health	benefits	associated	with	consumption	of	caffeine	and	other	methylxanthines	has	50	
been	accumulating	(Monteiro	et	al.,	2016,	Furman	et	al.,	2017,	Franco	et	al.,	2013).	These	benefits	51	
range	 from	 lowering	 of	 inflammation	 to	 the	 prevention	 of	 neurodegenerative	 disease	 (Chrysant	52	
(2017),	Kolahdouzan	M	and	Hamadeh	(2017).	The	effects	of	methylxanthines	are	primarily	thought	53	
to	be	due	to	their	binding	to	adenosine	receptors	(Monteiro	et	al.,	2016,	Salomone	et	al.,	2017).		54	
Primary	 Amine	 Oxidase	 (PrAO)	 is	 a	 copper-containing	 transmembrane	 glycoprotein	 that	 catalyses	55	
the	following	reaction:	56	
RCH2NH2		+		H2O		+		O2			---˃			RCHO		+		NH3		+		H2O2.	57	
It	 contains	 a	 cytoplasmic	 domain,	 a	 transmembrane	 segment	 and	 an	 extracellular	 domain.	 In	 the	58	
vascular	endothelium	the	extracellular	domain	may	be	cleaved	off	to	give	rise	to	a	circulating	form	59	
found	in	plasma.	 In	some	tissues,	the	membrane	form	acts	as	a	Vascular	Adhesion	Protein	(VAP-1)	60	
which	 is	 involved	 in	 the	 migration	 of	 leukocytes	 through	 the	 vascular	 endothelium	 at	 sites	 of	61	
inflammation	(Pannecoeck	et	al.,	2015).	This	extravasion	process	requires	the	amine	oxidase	activity	62	
catalyzed	 by	 PrAO	 to	 be	 intact	 (Noonan	 et	 al.,	 2013).	 	 Both	 the	 circulating	 plasma	 form	 and	 the	63	
membrane	associated	PrAO	are	active	 in	amine	oxidation	and	their	endogenous	substrates	 include	64	
methylamine	and	aminoacetone	 (see	 Lyles,	 1996).	 These	 substrates	are	 converted	by	PrAO	 to	 the	65	
toxic	aldehydes	formaldehyde	and	methylglyoxal	respectively:	such	aldehydes	can	crosslink	proteins	66	
in	vivo	giving	rise	to	vascular	damage	(e.g.	Unzeta	et	al.,	2007).		Finally,	it	has	been	shown	that	H2O2	67	
generated	by	 PrAO	has	 a	 signalling	 role	 in	 the	 regulation	of	 glucose	 uptake	 (see	McDonald	 et	 al.,	68	
2007).	69	
Raised	levels	of	PrAO	are	seen	in	a	number	of	disease	states	including	diabetes,	Alzheimer’s	disease	70	
and	 inflammation	(Pannecoeck	et	al.,	2015).	The	multiplicity	of	roles	for	PrAO	in	diverse	processes	71	
has	made	 it	an	 important	therapeutic	target	(O’Sullivan	et	al.,	2004).	 Inhibitors	of	PrAO	have	been	72	
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reported	 and	 its	 inhibition	 is	 known	 to	 have	 anti-inflammatory	 effects	 and	 to	 positively	 influence	73	
vascular	 health,	 neurodegenerative	 disease	 progress	 and	 lung	 fibrosis	 among	 other	 conditions	74	
(Horváth	et	al.,	2017,	Jarnicki	et	al.,	2017).			75	
Previous	studies	in	these	laboratories	explored	the	inhibition	of	PrAO	by	amine	compounds	in	food	76	
and	drugs	and	showed	that	caffeine	inhibited	bovine	PrAO	with	a	Ki	of	1.0mM	(Olivieri	et	al.,	2011,	77	
Olivieri	 and	 Tipton,	 2011).	 	 A	 subsequent	 study	 (Che	 et	 al.,	 2012)	 showed	 that	 caffeine	78	
administration	 to	 rats	 inhibited	 PrAO	 activity	 in	 serum,	 brain	 and	 adipose	 tissue	 and	 raised	 the	79	
possibility	 that	 caffeine	 could	 be	 used	 in	 treating	 PrAO-associated	 disease.	 	 Trials	 assessing	 the	80	
impact	of	caffeine	on	PrAO	activity	in	human	subjects	have	been	considered	but	have	not	yet	been	81	
initiated	 (see	 https://clinicaltrials.gov/ct2/show/NCT02098785).	 The	 ability	 of	 dietary	 caffeine	 to	82	
inhibit	PrAO	 in	vivo	 is	highly	significant	and	points	to	the	possibility	that	 ingested	food	compounds	83	
might	influence	PrAO	in	humans	in	a	similar	manner	to	that	seen	in	rat	tissues	(Che	et	al.,	2012).		84	
Recently,	 a	 study	 in	 human	 adipose	 tissue	 found	 that	 phenolic	 compounds	 in	 food	 blocked	 the	85	
downstream	effects	of	H2O2	produced	by	PrAO	albeit	without	directly	inhibiting	PrAO	activity	(Les	et	86	
al.,	2016).	 It	 is	plausible	 that	 food	components	could	be	 responsible	 for	modulating	 the	activity	of	87	
PrAO	and	that	such	modulation	might	be	a	significant	health	benefit	for	people	on	a	diet	enriched	in	88	
PrAO	inhibiting	components.		89	
While	our	previous	 findings	 showed	caffeine	 to	be	a	PrAO	 inhibitor	 there	 is	no	 information	 in	 the	90	
literature	 concerning	 PrAO	 inhibition	 by	 other	 methylxanthines.	 It	 was,	 therefore,	 of	 interest	 to	91	
examine	whether	 caffeine-related	 compounds	might	 contribute	 to	modulation	of	 PrAO	activity.	 In	92	
this	 study	 we	 examined	 theobromine,	 paraxanthine,	 theophylline,	 7-methylxanthine	 and	 their	93	
derivatives	 as	modulators	 of	 bovine	 PrAO	 activity.	 Caffeine	 is	 found	 in	 the	 diet	mainly	 in	 tea	 and	94	
coffee	 and	 as	 a	 component	 of	 energy	 drinks	 (Olivieri	 et	 al.,	 2011,	 Olivieri	 A	 and	 Tipton	 2011).	95	
Theobromine	 and	 theophylline	 are	 ingested	 in	 tea	 and	 chocolate	 respectively	 (Monteiro	 et	 al.,	96	
5	
	
2016);	paraxanthine	 is	 the	major	metabolite	of	 caffeine	 in	human	 tissues	and	7-methylxanthine	 is	97	
the	major	paraxanthine	metabolite	(Furman	et	al.,	2017).				98	
Materials	and	Methods	 	99	
Source	of	reagents:	Bovine	plasma	PrAO	was	obtained	from	Langanbach	Services	Ltd,	Bray,	Ireland.	100	
Other	chemicals	used	in	this	study	were	obtained	from	Sigma-Aldrich	unless	otherwise	indicated.	101	
Standard	enzyme	assay:	PrAO	activity	was	determined	by	following	H2O2	production	at	498	nm,	by	102	
the	method	 of	 Holt	 and	 Palcic	 (2006),	 in	 the	 presence	 of	 5.0	mM	benzylamine.	 The	 chromogenic	103	
solution	 for	 the	 detection	 of	 H2O2	 contained	 1	 mM	 vanillic	 acid,	 0.5	 mM	 4-aminoantipyrine	 and	104	
horseradish	peroxidase	(4	U/ml)	 in	a	‘physiological’	HEPES	buffer	system	(100	mM	HEPES,	280	mM	105	
NaCl,	10	mM	KCl,	4	mM	CaCl2,	2.8	mM	MgCl2).	The	pH	of	the	buffer	was	adjusted	to	7.4	with	0.1	M	106	
NaOH.	Assays	were	carried	out	 in	a	reaction	volume	of	300	µl	 in	96-well	microtitre	plates,	at	370C,	107	
using	 a	 SpectraMax	340PC	plate	 reader	 (Molecular	Devices,	 Inc.	 Sunnyvale,	 CA	94089-1136,	USA).	108	
Control	assays	 for	 the	coupling	system,	 in	 the	presence	of	10	µM	H2O2,	1	mU/ml	HRP	but	without	109	
PrAO,	 showed	 that	 none	 of	 the	 compounds	 affected	 the	 chromogenic	 detection	 system.	 Each	110	
compound	was	assayed	in	triplicate,	at	a	final	concentration	of	0.5	or	1.0	mM.		111	
Data	analysis	and	curve	fitting:	Data	for	each	methylxanthine	tested	as	an	inhibitor	was	obtained	in	112	
three	 separate	 experiment	 each	 conducted	 in	 triplicate.	 Data	 are	 reported	 as	mean	 +/-	 standard	113	
error	 of	 the	 mean.	 Dunnett’s	 test	 was	 used	 to	 assess	 the	 statistical	 significance	 of	 differences	114	
between	test	and	control	data.		115	
Kinetic	data	were	directly	fitted	by	non-linear	regression	to	the	Michaelis-Menten	equation	by	Graph	116	
Pad	Prism,	version	5.	Replots	were	fitted	by	linear	regression.		Double-reciprocal	plots	are	shown	for	117	
illustrative	purposes	only.		118	
	 	119	
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Results	120	
The	structures	of	the	compounds	tested	in	this	study	are	shown	in	Figure	1.	The	effect	of	caffeine,	121	
paraxanthine,	theophylline,	theobromine	and	7-methylxanthine	on	PrAO	at	fixed	concentrations	of	122	
500µM	and	1.0mM	was	examined	using	the	standard	assay	(Figure	2).			123	
……FIGURE	1	HERE…….	124	
Of	the	five	methylxanthines	tested	only	caffeine	and	theobromine	showed	substantial	 inhibition	of	125	
PrAO:	 surprisingly,	 the	other	 compounds	 tested;	 theophylline,	paraxanthine	and	7-methylxanthine	126	
had	relatively	little	effect.		 	127	
……FIGURE	2	HERE…….	128	
Since	caffeine	is	derived	from	xanthine	we	decided	to	test	xanthine	and	related	compounds	as	PrAO	129	
inhibitors.	 Figure	 3	 shows	 that	 neither	 xanthine,	 its	 metabolites	 hypoxanthine	 and	 uric	 acid,	 or	130	
imidazole	had	a	significant	inhibitory	effect	on	PrAO	activity	at	the	concentrations	used.			131	
……FIGURE	3	HERE…….	132	
Since	 theobromine	 was	 the	 only	 compound	 showing	 activity	 comparable	 to	 that	 of	 caffeine	 its	133	
interaction	with	PrAO	it	was	examined	in	greater	detail.		The	pattern	of	inhibition	with	theobromine	134	
was	 examined	 using	 benzylamine	 as	 substrate	 (Figure	 4a).	 A	 noncompetitive	 pattern	 of	 inhibition	135	
was	observed	and	a	Ki	of	276±44µM	was	estimated	from	a	slopes	replot	of	this	data	(Fig	4b).			136	
……FIGURE	4	HERE…….	137	
This	pattern	of	inhibition	is	similar	to	that	seen	with	caffeine	(Olivieri	and	Tipton	K.	(2011)	although	138	
the	Ki	estimated	was	significantly	lower	for	theobromine	than	for	caffeine.		139	
	140	
141	
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Discussion	142	
These	findings,	for	the	first	time,	identify	theobromine	as	a	modulator	of	bovine	PrAO	activity.	This	143	
expands	the	range	of	compounds	that	can	influence	this	important	enzyme.			Theobromine,	which	is	144	
a	constituent	of	cocoa	as	well	as	a	caffeine	metabolite	in	humans,	is	a	more	effective	inhibitor	than	145	
caffeine.	Theobromine	has	a	longer	plasma	half-life	than	caffeine	and	is	considered	less	active	in	the	146	
central	 nervous	 system	 and	 therefore	 is	 associated	 with	 less	 toxic	 side	 effects	 (Monteiro	 et	 al.,	147	
2017).		The	longer	half-life	of	theobromine	may	mean	its	effects	will	be	more	prolonged	than	those	148	
of	caffeine.		It	is	also	important	to	note	that	theobromine	may	be	formed	from	caffeine	breakdown	149	
in	vivo	(Oñatibia-Astibia	et	al.,	2017).	150	
In	 humans,	 the	 plasma	 concentration	 of	 theobromine	 has	 been	 reported	 to	 be	 as	 high	 as	 63µM	151	
following	the	consumption	of	chocolate	(Oñatibia-Astibia	et	al.,	2017).	The	relationship	between	Ki	152	
and	inhibitor	concentration	for	a	noncompetitive	inhibitor	is	given	by	equation	1:	153	
	154	
!"#$ !"" = !"#$1 + !!"	
Equation	1.	Noncompetitive	inhibition:	The	equation	shows	the	relationship	between	maximum	155	
velocity,	Vmax	app	(the	apparent	maximum	velocity),	in	the	presence	of	an	inhibitor	(I)	and	the	156	
maximum	velocity	in	the	absence	of	an	inhibitor	(Vmax).	The	term	Ki	is	the	inhibitor	binding	constant.		157	
	158	
Using	 63μM	 for	 [I]	 and	 276	μM	 for	 Ki	we	 can	 calculate	 that	 Vmax	 app	 =	 81%	of	 Vmax.	 Thus,	 the	159	
maximum	rate	of	PrAO	in	the	presence	of	63μM	theobromine	is	reduced	by	approximately	20%.			160	
A	study	of	plasma	PrAO	 levels	 in	human	type	1	diabetes	showed	PrAO	activity	of	1049	±	294mU/L	161	
versus	an	activity	of	749	±	204	mU/L	in	control	subjects	(mean	±	SD;	p	<	0.00001)	(see	Januszewski	et	162	
al.,	2014).	Thus,	a	difference	of	roughly	30%	in	PrAO	activity	correlated	with	renal	dysfunction	and	163	
vascular	inflammation.			A	similar	level	of	PrAO	elevation	was	observed	in	hypertensive	heart	disease	164	
Marinho	et	al,	2010).	Clearly,	relatively	modest	 increases	in	the	level	of	this	enzyme	correlate	with	165	
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disease	 progression.	 In	 this	 context	 the	 level	 of	 inhibition	 observed	 in	 these	 studies	 is	 potentially	166	
significant.		167	
The	net	effect	of	methylxanthines	on	PrAO	activity	may	be	complex	and	difficult	to	determine	with	168	
accuracy	since	these	compounds	may	derive	directly	from	various	components	of	the	diet	or	arise	as	169	
metabolites	 of	 caffeine.	 Assessing	 the	 combined	 effect	 of	 such	 compounds	will	 require	 animal	 or	170	
preferably	human	trials.	It	is	also	worth	noting	that,	in	recent	years,	theobromine	supplements	have	171	
become	widely	available	online	as	powders,	 capsules	and	pills	 for	 treatment	of	weight	 loss,	blood	172	
pressure	and	cancer,	among	other	conditions.			173	
Structure	 activity	 relationships:	 Of	 particular	 importance	 was	 the	 observation	 that	 none	 of	 the	174	
methylxanthines	besides	caffeine	and	theobromine	showed	significant	inhibition.	This	allowed	us	to	175	
identify	 structural	 features	 necessary	 for	 inhibition.	 Thus,	 7-methylxanthine,	 a	 caffeine	 derivative	176	
lacking	 a	 methyl	 group	 at	 position	 3,	 shows	 little	 inhibition.	 Similarly,	 theophylline,	 lacking	 the	177	
methyl	 group	 at	 position	 7,	 is	 relatively	 ineffective	 as	 an	 inhibitor.	 It	 is	 clear	 that	methylation	 of	178	
positions	3	and	7	on	xanthine	are	necessary	for	inhibition.		The	lack	of	significant	inhibition	by	these	179	
closely	related	compounds	suggests	that	other	elements	of	the	xanthine	structure	contribute	little	to	180	
inhibitor	binding.		The	lower	Ki	for	theobromine	relative	to	caffeine	may	be	due	to	the	formation	of	181	
hydrogen	bonds	between	the	nitrogen	in	position	1	and	amino	acid	side	chains	on	PrAO.	Imidazole	182	
was	 reported	 to	 be	 an	 inhibitor	 of	 PrAO	 at	 high	 concentrations	 (Elovaara	 et	 al.,	 2016)	 but	 at	 the	183	
highest	level	used	herein	(1.0mM)	showed	only	mild	inhibition	(Figure	3).		184	
Methylxanthine	binding	site:	The	pattern	of	inhibition	is	noncompetitive,	implying	that	theobromine	185	
does	not	directly	block	substrate	binding	but	still	affects	substrate	turnover.		This	pattern	is	normally	186	
interpreted	 as	 the	 binding	 of	 inhibitor	 to	 a	 site	 other	 than	 the	 active	 site	 (Figure	 5).	 Thus,	 the	187	
inhibitor	may	bind	to	both	free	enzyme	and	the	enzyme	substrate	complex.	However,	the	ping-pong	188	
mechanism	of	 PrAO-catalysed	 amine	oxidation	means	 that	 ligands	may	bind	 to	 both	oxidized	 and	189	
reduced	forms	of	this	enzyme	yielding	complex	kinetic	plots	(see	Holt	et	al.,	2008).		Noncompetitive	190	
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inhibition	might	be	expected	 if	 the	methylxanthines	bind	within	the	substrate	entrance	channel	of	191	
either	 oxidised	 or	 reduced	 forms	 of	 PrAO.  A	 similar	 noncompetitive	 pattern	 of	 inhibition	 was	192	
observed	with	caffeine	when	benzylamine	was	the	substrate	although	a	mixed	pattern	of	inhibition	193	
was	seen	when	methylamine	was	the	substrate	(Olivieri	and	Tipton,	2011).	194	
……FIGURE	5	HERE…….	195	
An	 imidazoline	binding	 site	on	PrAO	has	been	 indicated	 in	previous	 studies	 (Holt	et	al.,	 2008)	and	196	
two	imidazole	binding	sites	have	been	identified	on	a	crystal	structure	of	human	PrAO	(Elovaara	et	197	
al.,	2011).	The	crystal	structure	showed	imidazole	bound	to	the	topaquinone	(TPQ)	cofactor	of	both	198	
the	 oxidised	 and	 reduced	 forms	 of	 PrAO.	 	 It	 is	 possible	 that	 one	 of	 these	 sites	 might	 bind	 the	199	
methylxanthines	 of	 this	 study.	 Theobromine	 and	 caffeine	 presumably	 interact	 via	 hydrogen	 bond	200	
formation	with	 residues	 of	 PrAO.	 Comparison	with	 the	 other	 structures	 considered	 herein	 shows	201	
that	 inhibition	 is	 quite	 specific	 requiring	 the	 particular	 pattern	 of	 N-methylation	 only	 found	 in	202	
caffeine	and	theobromine.		203	
The	well-known	positive	effects	of	caffeine	and	theobromine	on	vascular	health,	 inflammation	and	204	
neurodegenerative	 disease	 have	 been	 variously	 attributed	 to	 binding	 at	 adenosine	 receptors,	205	
phosphodiesterase	 inhibition,	 binding	 to	 GABA	 receptors	 or	 calcium	 regulation	 (Monteiro	 et	 al.,	206	
2016).	 Inhibition	 of	 PrAO	 has	 not	 been	 considered	 as	 significant	 in	 this	 process;	 however,	 the	207	
benefits	ascribed	to	methylxanthines	mirror	those	associated	with	PrAO	inhibition.		It	is	conceivable	208	
that	 modulation	 of	 PrAO	 activity	 by	 ingested	 methylxanthines	 and	 their	 metabolites	 might	209	
contribute	 to	 lowering	 PrAO	 activity	 in	 vivo.	 This	 in	 turn	 might	 account	 for	 the	 known	 dietary	210	
advantage	associated	with	consumption	of	compounds	in	this	class.		211	
A	great	deal	of	effort	has	been	directed	towards	the	development	of	specific	inhibitors	of	PrAO	but	212	
efforts	 have	 been	 hampered	 by	 a	 lack	 of	 selectivity	 or	 because	 inhibitors	 contain	 highly	 reactive	213	
structural	elements	(see	O'Rourke	et	al.,	2008).	It	is	possible	that	the	caffeine/theobromine	binding	214	
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site	 identified	 here	 might	 offer	 an	 attractive	 target	 for	 PrAO	 inhibitor	 design	 since	 it	 can	 inhibit	215	
activity	 without	 affecting	 substrate	 affinity:	 a	 noncompetitive	 inhibitor,	 unlike	 a	 competitive	216	
inhibitor,	 will	 not	 be	 affected	 by	 fluctuations	 in	 the	 physiological	 concentration	 of	 substrates	217	
available	to	PrAO.			218	
It	 is	 worth	 noting	 that	 caffeine	 derivatives	 have	 been	 explored	 previously	 in	 the	 treatment	 of	219	
neurodegenerative	 disease	 (Petzer	 and	 Petzer	 2015,	 Pohanka	 2015).	 For	 example,	 substitution	 at	220	
position	 8	 in	 caffeine	 to	 give	 8-chlorostyrylcaffeine,	 produces	 a	 powerful	 reversible	 inhibitor	 of	221	
monoamine	oxidase	B	(Binda	et	al,	2006).	Likewise,	substitutions	on	the	nitrogen	atom	at	position	1	222	
of	 theobromine	 gives	 rise	 to	 the	 anti-inflammatory	 lisofylline	 and	 the	 antihistamine	 pentoxifylline	223	
(Pascal	et	al,	1985).	Di-substituted	derivatives	such	as	the	3,	8	substituted	compounds	bamiphylline,	224	
naxifylline	and	rolofylline,	with	increased	solubility,	have	also	been	investigated	as	cardioprotective	225	
drugs	(Szentmiklósi	et	al,	2011).	The	effects	of	many	of	these	drugs	on	MAO	and	PrAO	have	not	been	226	
assessed	 although	 there	 is	 evidence	 that	 the	 inhibition	 of	 both	 enzymes	may	 be	 beneficial	 in	 the	227	
management	of	neurodegenerative	diseases,	 in	combatting	oxidative	stress	(Liu	et	al,	2010)	and	in	228	
the	treatment	of	obesity	(Carpéné	et	al,	2007).	Thus,	theobromine	may	provide	a	useful	skeleton	for	229	
the	development	of	more	powerful	drugs	and	multi-target	directed	ligands.	These	findings	provide	a	230	
strong	impetus	to	extend	these	studies	to	human	tissues.	231	
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Figure	Legends	329	
Figure	 1:	 Structures	 of	 the	 methylxanthines	 considered	 in	 this	 study.	 These	 naturally-occurring	 compounds	 are	 all	 N-330	
methylated	derivatives	of	xanthine.		331	
Figure	 2.	 	 Inhibition	 of	 PrAO	 activity	 by	methylxanthines.	 	 Assays	 were	 carried	 out	 at	 370C	 and	 pH	 7.4	 as	 described	 in	332	
materials	and	methods.	The	control	was	a	standard	assay	of	PrAO	in	the	presence	of	5.0	mM	benzylamine.		The	data	shown	333	
are	the	mean	±	SEM	(n=3).	Asterisks	denote	a	significant	difference	between	treatments	and	the	control	(*P	≤	0.05;	**P	≤	334	
0.01;	***P	≤	0.001)	using	Dunnett’s	test.	335	
Figure	 3.	 	 Effect	 of	 xanthine	 and	 related	 compounds	 on	 PrAO	 activity.	 	 Assays	 were	 carried	 out	 at	 370C	 and	 pH	 7.4	 as	336	
described	in	materials	and	methods.	The	control	was	a	standard	assay	of	PrAO	in	the	presence	of	5.0	mM	Benzylamine.		All	337	
data	are	 the	mean±SEM	of	 three	 separate	determinations.	 Asterisks	 denote	a	 significant	 difference	between	 treatments	338	
and	the	control	(*P	≤	0.05;	**P	≤	0.01;	***P	≤	0.001)	using	Dunnett’s	test.	339	
Figure	4.	 (a)	Pattern	of	 inhibition	of	PrAO	by	 theobromine.	Assays	were	 carried	out	as	 indicated	 in	 the	methods	 section.	340	
Benzylamine	concentration	was	varied	between	1.0	and	5.0mM	at	various	concentrations	of	caffeine:	0,	100,	200,	300,	400,	341	
500,	600µM.	The	Lineweaver	Burk	plots	are	shown	for	illustrative	purposes	only:	each	data	set	was	fitted	to	a	rectangular	342	
hyperbola	and	Kmapp	and	Vmax	estimated	by	non-linear	 regression	with	 the	aid	of	Graph	Pad	Prism	5.0.	 (b)	A	 replot	of	343	
slopes	(Kmapp/Vmax)	for	each	line	in	Fig	4a	versus	theobromine	concentration	was	used	to	estimate	Ki.	A	Ki	of	276±	44	µM	344	
mean	±	SEM	(n=3)	was	estimated.		345	
Figure	 5.	 	 Noncompetitive	 inhibition	mechanism.	Where	 E	 represents	 enzyme,	 S,	 the	 substrate,	 P	 the	 product	 and	 I	 the	346	
inhibitor.	 The	 constant	K	 for	 substrate	binding	 is	unaffected	by	 the	binding	of	 inhibitor.	 The	 inhibitor	binding	constant	 is	347	
denoted	KI.	In	this	mode	of	inhibition	the	inhibitor	binds	equally	to	free	enzyme	and	enzyme-substrate	complex	(ES)	causing	348	
a	decrease	in	Vmax	but	not	affecting	Km.		The	binding	of	inhibitor	is	considered	to	be	independent	of	substrate	binding.	349	
	350	
	351	
	352	
	353	
	354	
	355	
Figure 1 
 
 
  
 
2 
CAFFEINE 
H3C 
CH3 
CH3 
H 
H3C 
CH3 
PARAXANTHINE 
H3C 
CH3 
H 
THEOPHYLLINE 
CH3 
CH3 
H 
THEOBROMINE 
CH3 
H 
H 
7-METHYLXANTHINE 
3 4 
5 8 
9 
1 6 7 
Figure 2 
 
 
+  
C
o n
tro
l
S e
m
ic
a r
b a
z i
d e
 C
o n
tro
l
C
a f
fe
in
e  
1m
M
C
a f
fe
in
e  
5 0
0  P
M
7 -
M
e t
h y
lx
a n
th
in
e  
1m
M
7 -
M
e t
h y
lx
a n
th
in
e  
5 0
0  
PM
P a
ra
x a
n t
h i
n e
 1
m
M
P a
ra
x a
n t
h i
n e
 5
0 0
 PM
T h
e o
b r
om
in
e  
1m
M
T h
e o
b r
om
in
e  
5 0
0  P
M
T h
e o
p h
y l
lin
e  
1m
M
T h
e o
p h
y l
lin
e  
5 0
0  P
M
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
A
ct
iv
it
y 
(%
 m
e
an
r 
SE
)
***
***
**
** **
**
***
***
** **
 
  
Figure 3 
 
A
ct
iv
it
y 
(%
 m
e
an
r 
SE
)
+  
C o
n t
ro
l
S e
m
ic a
rb
a z
id
e  
c o
n t
ro
l
X a
n t
h i
n e
 1
m
M
X a
n t
h i
n e
 5
0 0
 P
M
H y
p o
xa
n t
h i
n e
 1
m
M
H y
p o
xa
n t
h i
n e
 5
0 0
 P
M
U r
ic  
A c
id
 1
m
M
U r
ic  
A c
id
 5
0 0
 P
M
Im
id
a z
o l
e  
1 m
M
Im
id
a z
o l
e  
5 0
0  
PM
0
2 0
4 0
6 0
8 0
1 0 0
* * *
 
 
 
 
Figure 4a 
Ki Plot of Inhibition of PrAO with Theobromine
-400 -200 0 200 400 600 800
2
4
6
8
10
Ki  = 275.6 mM 
Theobromine Conc (mM)
1/
Sl
op
e
Figure 4b 
 Figure 5 
K 
Ki Ki 
k 
